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Abstract Lack of standardised Clostridium difficile testing is
a potential confounder when comparing infection rates. We
used an observational, systematic, prospective large-scale
sampling approach to investigate variability in C. difficile
sampling to understand C. difficile infection (CDI) incidence
rates. In-patient and institutional data were gathered from 60
European hospitals (across three countries). Testing method-
ology, testing/CDI rates and case profiles were compared be-
tween countries and institution types. The mean annual CDI
rate per hospital was lowest in the UK and highest in Italy (1.5
vs. 4.7 cases/10,000 patient bed days [pbds], p < 0.001). The
testing rate was highest in the UK compared with Italy and
France (50.7/10,000 pbds vs. 31.5 and 30.3, respectively,
p < 0.001). Only 58.4 % of diarrhoeal samples were tested
for CDI across all countries. Overall, only 64 % of hospitals
used recommended testing algorithms for laboratory testing.
Small hospitals were significantly more likely to use
standalone toxin tests (SATTs). There was an inverse correla-
tion between hospital size and CDI testing rate. Hospitals
using SATTor assays not detecting toxin reported significant-
ly higher CDI rates than those using recommended methods,
despite testing similar testing frequencies. These data are con-
sistent with higher false-positive rates in such (non-
recommended) testing scenarios. Cases in Italy and those di-
agnosed by SATT or methods NOT detecting toxin were sig-
nificantly older. Testing occurred significantly earlier in the
UK. Assessment of testing practice is paramount to the accu-
rate interpretation and comparison of CDI rates.
Introduction
While Clostridium difficile infection (CDI) is a key
healthcare challenge, standardised disease measurement
remains elusive [1–4]. Mandatory CDI reporting is rare,
although more countries are introducing or expanding sur-
veillance of healthcare-associated CDI [2, 3]. Guidelines
recommend early detection of CDI and active surveillance
as essential to disease control [5–7]. Reported CDI inci-
dence can vary markedly between hospitals and countries;
CDI rates across European countries varied ∼40-fold in
2008 (0.0–36.3/10,000 patient bed days [pbds], per hos-
pital) and 2013 (0.7–28.7/10,000 pbds) [8, 9]. Key CDI
risk factors, including age and antibiotic exposure, should
be similar across countries; thus, such high variability
suggests that other dominant factors influence reported
CDI rates.
A recent US study, based on data from 3.6 % of the popu-
lation, estimated a total of 453,000 cases in 2011 [4]. Notably,
a sensitivity analysis explored the effects of testing method:
the total number of cases could vary from 286,300 to 701,100
if the proportion of samples tested for CDI by polymerase
chain reaction (PCR) ranged from 0 to 100% [4]. Using single
C. difficile targets (e.g. toxin gene) can exaggerate reported
case rates, as such testing policies do not differentiate between
colonisation and true CDI [10–12]. The detection of
C. difficile toxin correlates with mortality, disease severity
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and complications [11, 13], but available assays are sub-opti-
mal, as standalone toxin tests (SATTs) have sub-optimal sen-
sitivity and specificity.
In addition to testing methodology, diagnostic intensity
(mostly driven by CDI awareness) is a key determinant of
reported rates [8, 14, 15]. In 2012, only ∼40 % of 482
hospitals across Europe were using recommended labora-
tory methods to diagnose CDI [8]. Furthermore, 23 % of
all CDI-positive samples identified at study coordinating
laboratories were never even tested at the submitting hos-
pital due to a lack of clinical awareness [8]. We have used
a systematic, observational prospective large-scale sam-
pling approach to investigate variability in C. difficile
sampling, testing and reported CDI rates.
Methods
Sixty hospitals across France, Italy and the UK (20 per coun-
try) were recruited by national coordinators to represent a
wide geographical area. Via a questionnaire, hospitals provid-
ed institutional data (size and type of institution) and details of
current CDI laboratory diagnostic methods and policies (April
2014 to March 2015). We obtained monthly data for hospital
in-patients on the numbers of enteropathogen and CDI tests,
and CDI-positive cases, along with case demographic data.
Cases were defined as ‘primary’ if the first case in the patient
or ‘recurrent’ if a second positive sample occurred within 2–8
weeks of a previous positive. All data were uploaded prospec-
tively by participating hospitals to a secure, dedicated, web-
based, study database. All data analyses were conducted by
the European coordinator.
Data analysis
The testing methodology, testing/CDI rates and case pro-
files were compared between countries and different sized
institutions. Hospitals were classified as small (<100,000
pbds per annum), medium (100,000–500,000) or large
(>500,000). Annual testing and case rates were calculated
per 10,000 pbds for each hospital, and mean rates were
compared between countries and between different sized
institutions. The mean CDI case incidence and patient
profiles were compared between hospitals using a recom-
mended testing algorithm (GDH/toxin or NAAT/toxin)
versus methods not detecting toxin (e.g. GDH/NAAT or
NAAT alone), SATT (e.g. toxin EIA alone) or a non-
recommended algorithm (e.g. GDH/toxigenic culture)
[1]. CDI and testing rates were compared by analysis of
variance (ANOVA), age distributions by Kruskal–Wallis
and proportions were compared by Chi-squared. Analysis
was performed on SPSS 19 (IBM).
This surveillance study was granted ethical approval by the
University of Leeds (SoMREC13032) for UK data collection
and European-wide analysis, and by the National Institute for
Infectious Diseases ‘Spallanzani’, Rome for Italian data col-
lection. Ethical approval was not required in France.
Results
Institutional data
Fifty-nine of 60 hospitals completed the questionnaire (one
missing in the UK). There were five small, 40 medium and
12 large hospitals; data on the number of pbds were not avail-
able for a further two hospitals. There were more small hos-
pitals in Italy than in either France or the UK; Italy had no
large hospitals (Table 1).
Testing and case rates: comparison between countries
and different sized institutions
The mean annual overall enteropathogen testing rate per hos-
pital was 107.4 tests/10,000 pbds, with significantly more
tests carried out in Italy than the other two countries
(p < 0.001) (Table 1). The UK had the highest rate of CDI
patient tests/10,000 pbds compared with Italy and France
(50.7 vs. 31.5 and 30.3, respectively, p < 0.001) (Table 1). If
the number of in-patient samples sent for enteropathogen de-
tection is used as a proxy for the number of diarrhoeal samples
submitted to the laboratory, then, overall, only 58.4 % of
diarrhoeal samples were tested for CDI across the three coun-
tries. The UK and France tested higher proportions of in-
patient diarrhoeal samples for CDI (68.5 and 59.4 %, respec-
tively) than Italy (31.8 %).
The mean annual CDI rate per hospital was 2.5/10,000
pbds, with the lowest incidence in the UK and the highest in
Italy (1.5 vs. 4.7 cases/10,000 pbds, respectively, p < 0.001)
(Table 1). The mean annual rate of laboratory-defined CDI
recurrence per hospital was 0.3/10,000 pbds; significantly
higher recurrence rates were reported in Italy than in the other
two countries (Italy 0.6 vs. France 0.4 and the UK 0.2/10,000
pbds, p = 0.026) (Table 1). The mean annual CDI testing and
CDI-positive rates were significantly higher in small hospitals
(55.8/10,000 pbds and 5.6/10,000 pbds, respectively) com-
pared with medium (46.2/10,000 pbds and 3.3/10,000 pbds,
respectively) and large hospitals (28.6/10,000 pbds and 1.5/
10,000 pbds, respectively) (p < 0.001 and p = 0.05) (Table 1,
Fig. 1 R2 = 0.972 and 0.9975, respectively, p < 0.001). Small
hospitals also had the highest annual rate of recurrence (0.9/
10,000 pbds, p < 0.001) (Table 1), although this was largely
driven by the high rate of recurrence in small hospitals in Italy
(Table 1).
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Testing methodology: impact on testing and case rates
Overall, 38/60 (63.3 %) hospitals used a recommended testing
algorithm. Significantly more hospitals in the UK (17/20,
85 %) used a recommended testing algorithm compared to
those in either France (13/20, 65%) or Italy (8/20, 40%); both
p = 0.001 (Table 3). Significantlymore hospitals in Italy (6/20,
30%) used SATT than institutions in either France (1/20, 5 %)
or UK (0 %); both p = 0.004 (Fig. 2). Small hospitals (3/5,
60 %) were significantly more likely to use SATT than medi-
um (3/40, 8 %) or large (1/12, 8 %) hospitals; both p = 0.005
(Fig. 2).
The mean annual hospital-reported CDI rate was signifi-
cantly higher for those institutions using methods that do not
detect toxin or SATT (5.2 and 4.0/10,000 pbds, respectively)
versus hospitals using recommended algorithms (2.0/10,000
Table 1 Annual testing,Clostridium difficile infection (CDI) and recurrence rates/10,000 patient bed days (pbds) per hospital for each country, and for
small (<100,000 pbds per annum), medium (100,000–500,000 pbds) or large (>500,000 pbds) hospitals
Country Size of
hospital
Number
of
hospitals
(n)
Average number
of faecal samples
tested for
enteropathogens/
10,000 pbds per
hospital per
annum (n)
Average number
of patients tested
for
enteropathogens
/10,000 pbds per
hospital per
annum (n)
Average
number of
faecal samples
tested for CDI/
10,000 pbds
per hospital per
annum (n)
Average
number of
patients tested
for CDI/
10,000 pbds
per hospital
per annum (n)
Average
number of
faecal samples
positive for
CDI/10,000
pbds per
hospital per
annum (n)
Average
number of
patients
positive for
CDI/10,000
pbds per
hospital per
annum (n)
Number of
recurrent
CDI cases/
10,000 pbds
per hospital
per annum
(n)
France No data 1 n/a n/a n/a n/a n/a n/a n/a
France Small 0 n/a n/a n/a n/a n/a n/a n/a
France Medium 13 72.3 54.8 40.7 34.3 3.5 3.2 0.4
France Large 6 51.4 40.2 26.1 21.6 2.2 2.1 0.3
France Overall 20 68.3 51.0 36.2 30.3 3.1 2.9 0.4
Italy No data 0 n/a n/a n/a n/a n/a n/a n/a
Italy Small 4 284.8 212.7 67.0 49.7 7.6 6.1 1.0
Italy Medium 16 140.1 90.5 37.1 30.1 4.8 4.6 0.6
Italy Large 0 n/a n/a n/a n/a n/a n/a n/a
Italy Overall 20 150.4 99.2 39.2 31.5 5.0 4.7 0.6
UK No data 1 n/a n/a n/a n/a n/a n/a n/a
UK Small 1 139.5 114.2 103.4 90.3 3.2 3.0 0.5
UK Medium 11 206.2 161.7 94.4 83.0 2.1 2.0 0.2
UK Large 6 75.9 35.8 42.4 32.1 1.1 1.1 0.2
UK Overall 19 123.9 74.1 64.2 50.7 1.6 1.5 0.2
Overall No data 2 n/a n/a n/a n/a n/a n/a n/a
Overall Small 5 262.8 197.8 72.5 55.8 7.0 5.6 0.9
Overall Medium 40 129.2 94.6 54.1 46.2 3.5 3.3 0.4
Overall Large 12 67.8 37.3 37.0 28.6 1.5 1.4 0.2
Overall Overall 59 107.4 69.2 50.3 40.5 2.7 2.5 0.3
R² = 0.972
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Fig. 1 Effect of size of the
hospital on Clostridium difficile
infection (CDI) testing and case
rates/10,000 patient bed days
(pbds) per hospital per annum. R2
(linear trendline) are for overall
values only. For CDI case rates,
Spearman’s r = 0.135, p < 0.001
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pbds; p < 0.001) (Table 3), despite testing rates being similar.
The CDI positivity rate was 2.5-fold higher when methods not
detecting toxin versus a recommended algorithm were used
(14.1 % vs. 5.4 %, p < 0.001) and 3.5-fold higher for SATT
(18.6 vs. 5.4 %, p < 0.001). In addition, hospitals using
methods that do not detect toxin or SATT had (non-
significantly) higher mean annual CDI recurrence rates (0.7
and 0.4/10,000 pbds, respectively) than those using a recom-
mended algorithm (0.3/10,000 pbds).
CDI case demographics
Between April 2014 and March 2015, there were 5876 report-
ed CDI cases, of which 4937 (84 %) were first episodes (data
unavailable for 176). Of 5855 cases with gender data avail-
able, there were slightly more females with CDI (3252, 55%).
There was a significant difference in the gender of cases
between countries; proportion of females, France 53.3 %,
Italy 58 % and the UK 56.5 % (p = 0.009) (Table 2). The
median age of CDI cases was 75 years [interquartile range
(IQR) 60–84, range 0–104], but 30 % were aged <65 years.
There was a significant difference in the median age and dis-
tribution of ages of cases between countries; CDI patients in
Italy were older than those in France and the UK (p < 0.001)
(Table 2). Additionally, the median ages of cases diagnosed in
hospitals using methods either not detecting toxin (77 years)
or SATT (81 years) were significantly older than those tested
in hospitals using the recommended algorithm (75 years, both
p < 0.001). Also, patients with recurrent CDI were significant-
ly older than those with primary infection (76 vs. 74 years,
p = 0.007).
Specialty data were available for 5919 CDI cases; 73.9 %
were in medical specialities, 12.7% surgery, 7.7 % ITU/HDU,
1.3 % obstetrics/gynaecology and 3.0 % paediatrics (Table 2).
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Table 2 Demographics of CDI-positive cases from each country and overall
Country France Italy UK Overall
Gender
No. of females/total 1334/2501 930/1604 988/1750 3252/5855
(% females) (53.3) (58.0) (56.5) (55.5)
Median age (years) 71 78 74 75
(IQR, range) (55–83, range 0–104) (67–85, range 0–101) (61–84, range 0–104) (60–84, range 0–104)
Specialty location of patient, n (%)
Medical 1895 (75.6) 1277 (78.3) 1201 (67.4) 4373 (73.9)
Surgical 227 (9.1) 143 (8.8) 380 (21.3) 750 (12.7)
ITU/HDU 261 (10.4) 105 (6.4) 91 (5.1) 457 (7.7)
Obstetrics/gynaecology 11 (0.4) 24 (1.5) 40 (2.2) 75 (1.3)
Paediatric 111 (4.4) 24 (1.5) 40 (2.2) 175 (3.0)
No data 2 (0.1) 58 (3.6) 29 (1.6) 89 (1.5)
Total 2507 1631 1781 5919
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There were more UK surgical patients than in France or Italy
(p < 0.001), and more ITU/HDU patients in France than in
Italy or the UK (p < 0.001).
Time from admission to testing
UK cases were tested significantly earlier (median day 3, IQR
0–13, range 0–520; p < 0.001) than in France (median day 6,
1–22, 0–3874) or Italy (median day 10, 3–20, 1–414). Almost
half (48.9 %) of UK CDI-positive samples were tested ≤48 h
after admission, compared with 27.5 and 34.3 % in Italy and
France, respectively.
Discussion
This pilot study demonstrates the feasibility of collecting and
comparing prospective data on CDI testing across hospitals
and countries. We have clearly shown the impacts of testing
policies and methodologies on the reported rates of CDI and
case demographics. There are three main drivers of CDI rates
that can distort true incidence: diarrhoea sampling frequency;
rate of CDI testing (testing/requesting frequency) and labora-
tory method(s). A European study in 2008 showed a close
correlation between testing frequency and reported CDI rate
[8]. Five years later, albeit using a considerably larger hospital
cohort, this association was much weaker, likely reflecting
greater heterogeneity of testing methods [8].
Targeted testing of ‘at-risk’ patients will also likely impact
on CDI rates. CDI patients in Italy were significantly older
than those in the other two countries. Either CDI cases in Italy
are genuinely older or, more likely, C. difficile testing is gen-
erally performed on older patients. Although older age is often
reported as a risk factor for CDI, this may, in fact, be a proxy
marker for co-morbidity risk [16]. We have shown previously
that CDI under-diagnosis is more likely to occur in younger
individuals, presumably due to the lack of clinical suspicion
and/or testing policies that give insufficient prominence to
(real or perceived) lower risk groups [8]. In the present study,
patients diagnosed by non-recommended methods were sig-
nificantly older than those identified by recommended testing
algorithms. It appears, therefore, that targeted testing and the
use of non-recommended testing methods may be linked.
Interestingly, whilst UK hospitals appear not to be targeting
C. difficile testing in the elderly, there is a clear bias towards
earlier sampling/testing, compared with practice in institutions
in either France or Italy; CDI cases were tested a median of 3–
7 days earlier in the former (median 3 vs. 6 and 10 days,
respectively; p < 0.001). Earlier CDI testing in the UK likely
reflects the desire to apportion cases as ‘community-’ (diag-
nosed before or within the first 2 days of hospital admission)
rather than ‘hospital-acquired’ (diagnosed after 2 days of hos-
pital admission); notably, there are financial penalties
associated with excess ‘hospital-acquired’ CDI cases in the
UK. Earlier testing is also likely to be partly driven by differ-
ing country policies for sample submission; in France and
Italy, sampling is recommended after 48 h of diarrhoea,
whereas in the UK, this can occur after only one diarrhoeal
episode [17]. It is possible that such earlier testing will result
in higher reported CDI rates, as some cases would have re-
solved without treatment.
Sub-optimal CDI diagnosis is still prevalent within Europe
[8, 14, 15], despite guidelines having been issued in 2009 [1].
Only 64 % of the 60 hospitals in the present study used rec-
ommended laboratory testing algorithms [1]. More UK hospi-
tals used recommended algorithms for CDI diagnosis (85 %
vs. 40–65%), reflecting performance management of national
guidelines that were issued in 2012 [17]; indeed, the UK rate
of ‘recommended’ testing has increased since 2013 (76 %)
[8]. According to our data, almost a third of Italian hospitals
are still using SATT for CDI diagnosis, despite clear evidence
of their poor prognostic performance (i.e. sub-optimal positive
and negative predictive values) [18, 19]. Small hospitals were
significantly more likely to use SATT, although all 3/5 such
hospitals were in Italy; thus, this association may be a country
effect and/or related to institutional size. There was, however,
a significant inverse relationship between hospital size and
both C. difficile testing rate and CDI case frequency (Fig. 1).
It is likely that high CDI rates in small hospitals reflect more
testing. However, it is possible that there is also some con-
founding here, as the use of SATT is associated with a high
false-positive CDI rate [11, 18, 19]. In addition, smaller hos-
pitals may have a different patient and wardmix to that seen in
larger institutions; this again may impact on CDI rates.
In hospitals using diagnostic methods that only detected
toxin or did not detect toxin at all, CDI rates were significantly
higher than in institutions using recommended algorithms,
despite testing rates being similar (Table 3). It could be argued
that assays not detecting toxin (including standalone NAAT
testing) are more sensitive and, thus, are detecting more cases,
which are missed by other methods. However, several studies
have shown that diarrhoeal patients that are C. difficileNAAT-
positive only do not have higher mortality or CDI complica-
tions than controls, in contrast to cases defined by the presence
of faecal C. difficile toxins [10–13]. It is likely, therefore, that
the higher case rates seen in hospitals not using toxin detection
are due to the detection of colonised patients in addition to
those with true CDI.
There are several limitations to this pilot study. Firstly, this
was an observation study that collected data at the laboratory
level, with no information available on symptom severity; we
presumed that diarrhoea was present, based on assumed clin-
ical decisions to sample and/or request C. difficile testing.
Institutions that participated in this study were chosen by the
study coordinators and may have had a higher CDI awareness
and/or rates; however, institutional selection was intended to
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be ‘representative’ of hospitals nationally, and to cover a wide
geographical spread. We did not collect demographic data for
patients with samples that tested negative for C. difficile/CDI.
This would provide better evidence for the age distribution of
cases/controls and help to show how testing is targeted. Such
data will be collected in the follow-on full LuCID study,
which will also expand to include a total of 40 hospitals in
each country and two more countries (Spain and Germany).
The additional countries and hospitals will increase the sizes
of the (at present) small sub-groups, such as small hospitals
and CDI recurrences. As patient bed day data were collected
annually rather than per month, we were not able to determine
with confidence possible seasonality of either CDI testing or
case rates. These limitations will also be addressed in the full
LuCID study.
Our pilot results show that it is important to understand the
context of sampling, testing and methodology in order to in-
terpret reported CDI rates. It is essential that studies either take
such potential confounders into account when interpreting da-
ta, and, ideally, that large, multi-centre, multi-country studies
are used to determine the true epidemiology of CDI.
Additionally, we have shown that inclusive testing with rec-
ommended diagnostic methodologies is associated with lower
reported rates of CDI. Theoretically, increased awareness of
true CDI cases enhances opportunities to implement appropri-
ate and targeted infection prevention and control measures.
‘Missed’ cases, either through lack of clinical suspicion or
the use of non-recommended laboratory diagnostics, may fa-
cilitate the transmission ofC. difficile because of unrecognised
reservoirs of infection. Conversely, false-positive cases may
be receiving antibiotics for assumed CDI that could be detri-
mental, potentially having deleterious or resistance selection
effects on gut microbiota and possible induction of true CDI in
some instances.
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